Category - Developments

Aphria (TSX:APH; OTCQB:APHQF) has invested $11.5-million in Scientus Pharma’s HydRx Farms unit by way of a 2-year secured debenture convertible into common shares of Scientus Pharma at a rate of $2.75 a share...

Microbix Biosystems (TSX:MBX) reported record revenue for the fiscal third quarter ended June 30, 2017 of $2.8-million, up 23% from the same quarter a year ago. Net profit was $188,646, compared with $47,953 a year...

Closely-held Contextual Genomics has teamed up with CORE Diagnostics to introduce its Find-It genomic test in India. The Find-It test evaluates the mutation status of tumor DNA at more than 120 well-characterized...

IntelGenx Technologies (OTCQX:IGXT; TSXV:IGX) closed a second tranche of its prospectus offering of convertible debentures, raising additional proceeds of CDN $762,000. Together with more than CDN $6.8-million principal...

Microbix Biosystems (TSX:MBX) agreed to supply an existing long-term customer with an increasing quantity of its viral antigen products over the next five years, with an option to extend that term. Microbix’s customer...

Theratechnologies (TSX:TH) has been notified by its partner, TaiMed Biologics of Taiwan, that the FDA has completed the pre-license inspection of the WuXi Biologics facility, where Theratechnologies’ ibalizumab will be...

Profound Medical (OTCQX:PRFMF; TSXV:PRN) has completed the acquisition of the Sonalleve MR-HIFU business from Royal Philips (NYSE:PHG; AEX:PHIA). Sonalleve MR-HIFU is an innovative therapeutic platform that combines...

Titan Pharmaceuticals (NASDAQ:TTNP) has entered into a venture loan and security agreement with Horizon Technology Finance (NASDAQ:HRZN), which provides Titan with up to $10-million of available borrowing capacity. A...

BioLight Life Sciences (TASE:BOLT) announced successful results from its glaucoma insert, VS101, (Eye-D latanoprost) in a Phase 1/2a clinical trial, which demonstrated its ability to lower intraocular pressure (IOP) for...

Theratechnologies’ (TSX:TH) presented results on HIV susceptibility to ibalizumab from a Phase 2b trial, along with new findings for EGRIFTA (tesamorelin for injection), at the 9th IAS Conference on HIV Science in Paris...